Corui Technology Secures Tens of Millions in Series A1 Funding to Advance China's First Self-Developed UHPLC Systems
VCBeat has learned at the earliest opportunity that a high-end liquid chromatography supplierChengdu Kerui Science And Technology Co., Ltd.(hereinafter referred to as"Kerui Technology") recently completedTens of millions of RMB in Series A1 financing, this round of financing was led byFor Future CapitalInvestment,FarStar CapitalServed as the exclusive financial advisor for this round of financing. The funds raised will be allocated to R&D investment and commercialization.
Chengdu Kerui Science And Technology Co., Ltd. was established in 2016, committed to becoming a premier scientific instrument provider integrating the R&D, manufacturing, sales, and after-sales service of chromatography instruments, chromatography workstations, and their accessories.
The company adheres to the R&D philosophy of “grounded in fundamental science and technology,” bringing together mechanical, software, and electronics experts with years of industry experience, as well as a world-class analytical equipment marketing team. It emphasizes rational, objective, and constructive methodologies, committed to achieving long-term success.
From basic R&D to product finalization, and then to mass production and customized manufacturing, Kerui Technology has repeatedly improved key components and materials from an engineering perspective, optimizing processing capabilities and production processes. Leveraging its own strengths and driving innovation from the ground up, Kerui Technology has broken through the “chokehold” constraints facing domestic high-end liquid chromatography, emerging as a leader in this specialized segment of the high-end liquid chromatography market.
Kerui Technology developed China's first independently developed UHPLC (Ultra-High Performance Liquid Chromatography) system,Commercialization has already been achieved.。
APUS PLUS Ultra-High Performance Liquid Chromatograph
Liquid chromatography, as a critical separation and analytical instrument, is widely used in pharmaceutical companies and clinical settings. Due to insufficient technological accumulation, domestically produced liquid chromatographs have long been subject to foreign monopoly, with Chinese-made equipment confined to low-end markets such as food testing and environmental monitoring, resulting in extremely low product value-added. There is an urgent need for fundamental innovation in high-end domestic liquid chromatography systems to achieve technological breakthroughs and mitigate the risk of being constrained by core technology bottlenecks.
After nearly a decade of intensive efforts in foundational technologies, Chengdu Kerui Science And Technology Co., Ltd. has gradually achieved independent research and development of core components, including pressure sensors, gradient proportioning valves, six-port valves, autosamplers, and column ovens. Several of these technologies have broken through the monopoly and blockade imposed by foreign patents, resulting in a localization rate for the complete instruments exceeding 90%.
Validated by multiple downstream customers, the product demonstrates superior performance comparable to top global brands, along with high equipment stability, thereby addressing long-standing issues with domestic equipment such as inflated specifications and poor reliability. Built on years of R&D accumulation, the company has established sustained, leading independent innovation capabilities in the field of analytical instrumentation, with continuous R&D and innovation across multiple product lines.
Based on a solid technical foundation, Chengdu Kerui Science And Technology Co., Ltd. has establishedClinical LC-MS/MS, TDM (Therapeutic Drug Monitoring)and other product lines, achieving large-scale commercialization.
In the field of clinical LC-MS, Kerui Technology has established stable strategic partnerships with multiple leading domestic mass spectrometry brands.Some products have already begun large-scale sales, and it is expected that multiple products will obtain regulatory approval next year, enabling their widespread entry into hospitals.Two-Dimensional Liquid Chromatography System for Blood Drug Concentration AnalysisRegulatory approval has been obtained, with large-scale volume ramp-up imminent.
In the future, Kerui Technology will concentrate its efforts on promoting the industrialization of domestically produced liquid chromatography, focusing primarily on two aspects.
1. Develop software systems with stronger compliance;Helping domestically produced liquid chromatography systems penetrate the pharmaceutical industry and broader markets more rapidly.
On the other hand, it involves developing automated sample preparation equipment that is better suited to specific application scenarios.It can be integrated with liquid chromatography, mass spectrometry, and even other types of analytical instruments to create an assembly-line-style laboratory analysis system, achieving full automation from sample pretreatment to analysis. In the future, this system is expected to be applied in various fields such as clinical diagnostics, food safety, environmental monitoring, and pharmaceuticals, thereby truly embodying the values of Chengdu Kerui Science And Technology Co., Ltd.: integrating applications into scenarios, simplifying analysis, and transforming lives through science.
Zhao Yang, Partner at For Future Capital Management“For Future Capital expresses its gratitude to the Chengdu Kerui Science And Technology Co., Ltd. team for their trust and is honored to participate in this round of investment in Kerui Technology. Liquid chromatography systems are core equipment in the pharmaceutical and clinical sectors, where Chinese enterprises have historically failed to achieve breakthroughs in underlying technologies. Technological competition in biomedicine represents a critical frontier in future international rivalry; only by placing core technologies in the hands of Chinese enterprises can we truly seize the initiative in competition and development. As a fundamental R&D tool, the underlying technology of liquid chromatography constitutes one of the most urgent ‘chokepoint’ technologies requiring immediate breakthrough. This involves not only foundational theories but also advancements in technical principles and core components, presenting immense challenges. Over the past decade, we have been privileged to witness Kerui Technology’s growth from a small startup into a significant player, gradually breaking through the technological barriers established by overseas giants. The company has not only developed China’s first ultra-high-performance liquid chromatography (UHPLC) system but also achieved independent R&D of core components such as six-port valves. For Future Capital will continue to support Kerui Technology’s commercialization efforts in the innovative drug and clinical sectors, helping Kerui become an equipment R&D enterprise with global competitiveness.”